Lymphopenia and accidental splenic doses for locally advanced gastric cancer

38th Annual Meeting of the European-Society-for-Radiotherapy-and-Oncology (ESTRO) -- APR 26-30, 2019 -- Milan, ITALYWOS: 000468315603357European Soc Radiotherapy & Onco

Can we define any marker associated with brain failure in patients with locally advanced non-small cell lung cancer? [Peut-on définir un marqueur associé à une irechute cérébrale chez les patients atteints d'un cancer du poumon non à petites cellules localement évolué ?]

2-s2.0-85099121204Purpose: To define the factors which may be related to brain metastasis (BM) in patients with locally advanced non-small cell lung cancer (LA-NSCLC) who developed brain metastases after definitive treatment. Patients and methods: A total of 208 patients with LA-NSCLC, without BM who received definitive radiotherapy (RT) or RT + chemotherapy (CT) between January 2005 and January 2016 were evaluated retrospectively. Platelet, neutrophil, lymphocyte counts, LDH, CRP, Hb levels, neutrophil-to-lymphocyte radio (NLR), platelet-to-lymphocyte radio (PLR), advanced lung cancer inflammation index (ALI) and FDG-PET/CT parameters (SUVmax of the primary tumor and mediastinal lymph nodes), and patient characteristics were evaluated for brain metastasis free survival (BMFS). Results: Median follow-up duration was 25 months (range: 3–130 months). Cut-off values for platelet, NLR, PLR, LDH, CRP, and Hb were 290 × 103/?L, 2.6, 198, 468 IU/L, 2.5 mg/dL, and 11.5 g/dl. We defined each parameter as low or high according to the cut-off values. 56 patients (26.9%) developed brain metastases during follow-up. In univariate analysis, high NLR (P = 0.001), PLR (P = 0.037), LDH (P = 0.028), CRP (P = 0.002) values, value ? 7.5 for lymph nodes (P = 0.005) and low ALI value (P = 0.002) were poor prognostic factors for BMFS. In multivariate analysis, high NLR (P = 0.022), PLR (P = 0.017), CRP (P = 0.006), stage ? IIIB disease (P < 0.001), multi-stational N2 disease (P = 0.036), adenocarcinoma histology (P < 0.001) and SUVmax value ? 7.5 (P = 0.035) were poor prognostic factors for BMFS. Conclusions: High NLR, PLR, LDH, CRP values, SUVmax values for lymph nodes, and low ALI which indicates high tumor burden were additional prognostic factors besides stage, histology, and lymph node status. © 2020 Société française de radiothérapie oncologique (SFRO

Prognostic Factors Affecting Brain Metastasis-Free Survival in Non-Small Cell Lung Cancer Patients

WOS: 000492162205012[No abstract available

Geriatric Stage III NSCLC: Which scoring systems could guide us better to predict treatment outcome?

[No Abstract Available

Does neoadjuvant rectal score predict treatment outcomes better than the all grading systems used in neoadjuvantly treated rectal cancer?

Background: /Objective: To compare the prognostic value of the yield pathologic (yp) stage, used 4 tumor regression grading (TRG) systems, and neoadjuvant rectal score(NARS) in patients with locally advanced rectal cancer (LARC) who received long-term neoadjuvant chemoradiotherapy (nCRT). Methods: Between 2005 and 2017, we included 302 patients with LARC who treated with nCRT. Postoperative pathological responses were graded by using Dworak, American Joint Committee on Cancer, Mandart, Memorial Sloan Kettering Cancer Center, grading systems and NARS([5ypN-3(kT-pT)+12]2/9,61) calculations. Their results were compared in terms of treatment outcomes. Results: The median follow-up time was 51 months (range 5–136). There was a significant relation between cT stage and the response in used grading systems(p 0,001). Median overall(OS), local recurrence free(LRFS), and distant metastasis free(MFS) survival rates were 50, 48, and 45 months, respectively. 5-year OS, LRFS, and MFS rates were 71%, 92%, and 72%, respectively. According to the NARS and treatment response grating systems, a significant difference was found between the low risk and high risk groups in terms of OS, LRFS, and MFS rates. While it was not seen any difference in terms of OS and MFS, NARS was found to predict LRFS better than other grading systems. In multivariate analysis, high NARS was found to be correlated with worse OS and worse MFS. On the other hand, pCR was the another important factor affecting treatment outcomes. Conclusions: While used systems except NARS group patients according to ypT status in surgical tissue, NARS add the value of ypN status in addition to ypT status. It could be suggested to use NARS to predict LRFS. © 2022 Asian Surgical Association and Taiwan Robotic Surgery Associatio

Results of hypofractionated whole brain radiotherapy (2x8 Gy) for patients with brain metastases from lung cancer

WOS: 000292578200006PubMed ID: 21766491Purpose: To evaluate the clinical and radiologic response rates, toxicity and tolerability of 2x8 Gy whole brain radiotherapy (WBRT) in lung cancer patients with brain metastases (BM). Methods: WBRT was delivered to 126 lung cancer patients with BM during 2002-2006. External beam RT was delivered with a fraction dose of 8 Gy on the same day of each consecutive week Tumor and symptom response and toxicity were recorded at every follow-up. Recursive partitioning analysis (RPA) and the new Graded Prognostic Assessment (GPA) were used for analysis of overall survival (OS). Results: Twenty-three patients had small cell (SCLC) and 103 had non small cell lung cancer Pretreatment median Karnofsky performance score (KPS) was 70 (range 20-90). Clinical response rates were as follows: complete 31%; good partial 30.2%; partial 21.4%; stable 7.9%; and progressive 5.6%. Median palliation and survival duration was 57 and 80 days, respectively. Two- and 6-month survival rates (SR) were 59.5% and 25.4%, respectively. According to recursive partitioning analysis (RPA) 6-month SR for groups 1, 2 and 3 were 61.5, 41.6 and 33.9%, respectively (p=0.002). Six-month SR for the new Graded Prognostic Assessment (GPA) were: GPA 0-1, 7%; GPA 1.5-2.5, 34.2%; GPA 3, 25%; and GPA 3.5-4.0, 66.6% (p=0.0003). Conclusion: 2x8 Gy WBRT was found to be feasible. However the late morbidity of this schedule is unknown so its use could be restricted to patients with poor performance status, with a short life expectancy and/or social problems, unlikely to tolerate more protracted radiotherapy regimens

Prognostic Value of Volumetric PET Parameters in Patients with Locally Advanced Rectal Cancer

38th Annual Meeting of the European-Society-for-Radiotherapy-and-Oncology (ESTRO) -- APR 26-30, 2019 -- Milan, ITALYWOS: 000468315604023European Soc Radiotherapy & Onco